natgillin/translations-raw huggingface dataset:
The filgrastim in Accofil is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce filgrastim.
Filgrastim v zdravilu Accofil se pridobiva z metodo, imenovano „tehnologija rekombinantne DNK“: izdelajo ga bakterije, v katere so vstavili gen (DNK), s pomočjo katerega lahko tvorijo filgrastim.
The filgrastim in Grastofil is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce filgrastim.
Filgrastim v zdravilu Grastofil se proizvaja po metodi, imenovani „tehnologija rekombinantne DNK“, pri kateri se v bakterije vstavi gen (DNK), ki jim omogoča tvorjenje filgrastima.
The filgrastim in Lonquex is produced by a method known as ‘recombinant DNA technology’: it is made by bacteria into which a gene (DNA) has been introduced that makes the bacteria able to produce the filgrastim protein.
Filgrastim v zdravilu Lonquex se pridobiva s t. i. „tehnologijo rekombinantne DNK“, pri kateri v bakterije, ki so jim vstavili gen (DNK), postanejo sposobne tvoriti beljakovino filgrastim.
The filgrastim in Neulasta is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce filgrastim.
Filgrastim v zdravilu Neulasta se proizvaja po metodi, imenovani „tehnologija rekombinantne DNK“, pri kateri bakterija prejme gen (DNK), s katerim lahko tvori filgrastim.
The filgrastim in Neupopeg is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce filgrastim.
Filgrastim v zdravilu Neupopeg se proizvaja po metodi, imenovani „tehnologija rekombinantne DNK“: encim proizvede bakterija, ki je prejela gen (DNK) s pomočjo katerega postane sposobna tvoriti filgrastim.
The film coating contains: hypromellose (E464), titanium dioxide (E171), macrogol 400, yellow iron oxide (E172), and carnauba wax.
Filmska obloga vsebuje: hipromelozo (E464), titanov dioksid (E171), makrogol 400, rumeni železov oksid (E172) in karnauba vosek.
The film- coated tablets can be taken with or without food.
Tableto lahko bolnik zaužije s hrano ali brez.
The film-coat contains stearic acid (E570b), hypromellose (E464), microcrystalline cellulose (E460), titanium dioxide (E171), yellow iron oxide dehydrate (E172), red iron oxide dehydrate (E172) and talc (E553b).
Filmska obloga vsebuje stearinsko kislino (E570b), hipromelozo (E464), mikrokristalno celulozo (E460), titanov dioksid (E171), rumeni železov oksid dihidrat (E172), rdeči železov oksid dihidrat (E172) in smukec (E553b).
The film-coated tablet (tablet) is a, oval, biconvex, brick red coloured 19.3 x 9.3 mm tablet with bevelled edges and the inscription 145/40 on one side and the Abbott logo  on the other side.
Filmsko obložena tableta (tableta) je ovalna, bikonveksna, opečnato rdeče obarvana tableta velikosti 19,3 x 9,3 mm s posnetimi robovi in napisom 145/40 na eni strani in logotipom podjetja Abbott  na drugi strani.
The film-coated tablet (tablet) is a, oval, biconvex, tan coloured 19.3 x 9.3 mm tablet with bevelled edges and the inscription 145/20 on one side and the Abbott logo  on the other side.
Filmsko obložena tableta (tableta) je ovalna, bikonveksna, bež obarvana tableta velikosti 19,3 x 9,3 mm s posnetimi robovi in napisom 145/20 na eni strani in logotipom podjetja Abbott  na drugi strani.
The film-coated tablet is oval-shaped, green, marked with "144" on one side.
Filmsko obložena tableta je ovalne oblike, zelene barve in ima na eni strani oznako "144".
The film-coated tablet is oval-shaped, pink, marked with "227" on one side.
Ovalna, rožnata, filmsko obložena tableta, z oznako "227" na eni strani.
The film-coated tablet should be swallowed whole.
Filmsko obložena tableta se mora pogoltniti cela.
The film-coated tablets (tablets) are white to off white, oblong, convex, embossed ‘15 / 850’ on one face and ‘4833M’ on the other.
Filmsko obložene tablete (tablete) so bele ali skoraj bele barve, podolgovate, z oznako ‘15 / 850’ na eni in ‘4833M’ na drugi strani.
The film-coated tablets (tablets) are white to off-white and triangular-shaped.
Filmsko obložene tablete (tablete) so bele do sivobele barve in trikotne oblike.
The film-coated tablets are beige, oval, debossed with “770” on one side and plain on the other.
Filmsko obložene tablete so ovalne oblike, bež barve, ki imajo na eni strani vtisnjeno oznako "770", na drugi strani pa so brez oznake.
The film-coated tablets are light peach colored, oblong shaped, biconvex, 11.4 mm in length and 5.3 mm in width, debossed with ‘150’ on one side and plain on other side.
Filmsko obložene tablete so svetlo breskove barve, podolgovate oblike, bikonveksne, dolžine 11,4 mm in debeline 5,3 mm z vtisnjeno oznako »150« na eni strani in brez oznake na drugi strani.
The film-coated tablets are light pink to pink, film coated, capsule shaped tablets.
Filmsko obložene tablete so nežno rožnate do rožnate, v obliki kapsule.
The film-coated tablets are modified capsule-shaped, pale yellow to light-tan and debossed with ‘FX75’ on one side.
Filmsko obložene tablete so bledo rumene do svetlo rjave barve, v obliki modificirane kapsule, z vtisnjeno oznako »FX75« na eni strani.
The film-coated tablets are modified capsule-shaped, pink-orange to peach and debossed with ‘FX100’ on one side.
Filmsko obložene tablete so rožnato oranžne do breskove barve, v obliki modificirane kapsule, z vtisnjeno oznako »FX100« na eni strani.
The film-coated tablets are not breakable and are to be swallowed whole, with water.
Filmsko obloženih tablet se ne sme lomiti in jih je treba zaužiti cele z vodo.
The film-coated tablets are of oblong shape and white to off-white in colour, engraved L2/IT.
Filmsko obložene tablete so podolgovate oblike in bele do sivo bele barve z oznako L2/IT.
The film-coated tablets are oval biconvex light peach, 11.5 mm x 5.4 mm with inscription “C” on one side and “150”on the other side.
Filmsko obložene tablete so ovalne, bikonveksne filmsko obložene tablete, svetlo breskove barve, 11,5 mm x 5,4 mm z oznako »C« na eni strani in »150« na drugi strani.
The film-coated tablets are oval biconvex light peach, 16.0 mm x 8.5 mm with inscription “C” on one side and “500”on the other side.
Filmsko obložene tablete so ovalne, bikonveksne filmsko obložene tablete, svetlo breskove barve, 16,0 mm x 8,5 mm z oznako »C« na eni strani in »500« na drugi strani.
The film-coated tablets are pink, round and biconvex.
Filmsko obložente tablete so rožnate, okrogle in bikonvensne.
The film-coated tablets are provided in bottles containing 30 or 90 tablets.
Filmsko obložene tablete so na voljo v plastenkah, ki vsebujejo po 30 ali 90 filmsko obloženih tablet.
The film-coated tablets are white to off white, oblong shaped, biconvex, 14.6 mm in length and 6.7 mm in width, debossed with ‘300’ on one side and plain on other side.
Filmsko obložene tablete so svetlo breskove barve, podolgovate oblike, bikonveksne, dolžine 14,6 mm in debeline 6,7 mm z vtisnjeno oznako »300« na eni strani in brez oznake na drugi strani.
The film-coated tablets are white to off-white, oval shaped and embossed with the number “60” on one side and “N” on the other side.
Filmsko obložene tablete so bele do belkaste, ovalne tablete z vtisnjeno številko 60 na eni strani in črko N na drugi strani tablete.
The film-coated tablets are white, round biconvex tablets supplied in Polyamide/Al/PVC - Aluminum foil blister.
Filmsko obložene tablete so bele, okrogle, bikonveksne tablete na voljo v poliamid/Al/PVC – aluminijasto folijo.
The film-coated tablets can be taken with or without food.
Bolnik lahko filmsko obložene tablete zaužije s hrano ali brez nje.
The film-coated tablets can be taken with or without food.
Filmsko obložene tablete lahko jemljete s hrano ali brez.
The film-coated tablets can be taken with or without food.
Filmsko obloženo tableto lahko bolnik zaužije s hrano ali brez.
The film-coated tablets can be taken with or without food.
Tableto lahko bolnik zaužije s hrano ali brez.
The film-coated tablets consist of a core tablet, surrounded by a film coating to prevent exposure of health care professionals to the active substance.
Filmsko obložene tablete so sestavljene iz jedra, ki je obdano s filmsko oblogo.
The film-coating consists hypromellose, macrogols (8000), titanium dioxide (E171), talc and ferric oxide red (E172).
Filmsko oblogo sestavljajo hipromeloza, makrogoli (8000), titanov dioksid (E171), smukec in rdeči železov oksid (E172).
The film-coating contains hypromellose, polysorbate 80, glycerol 85%, sucrose, yellow iron oxide (E172), red iron oxide (E172) and titanium dioxide (E171), magnesium stearate.
Filmska obloga vsebuje hipromelozo, polisorbat 80, glicerol 85 %, saharozo, rumeni železov oksid (E172), rdeči železov oksid (E172), titanov dioksid (E171) in magnezijev stearat.
The film-coating contains partly hydrolysed polyvinyl alcohol, talc, macrogol, soybean lecithin, yellow iron oxide (E 172), red iron oxide (E 172) and titanium dioxide (E 171).
Filmska obloga vsebuje delno hidrolizirani polivinil alkohol, smukec, makrogol, sojin lecitin, rumeni železov oksid (E172), rdeči železov oksid (E172) in titanov dioksid (E171).
The film-coating contains poly(vinyl alcohol) - partially hydrolysed, macrogol 3350, titanium dioxide (E171), talc, sunset yellow FCF (E110).
Filmska obloga tablete vsebuje polivinilalkohol (delno hidroliziran), makrogol 3350, titanov dioksid (E171), smukec, barvilo oranžno FCF (E110).
The film-coating contains polyvinyl alcohol, titanium dioxide (E171), - macrogol, talc, iron oxide red (E172).
Filmska obloga vsebuje polivinilalkohol, titanov dioksid (E171), makrogol, smukec, rdeči železov oksid (E172).
The film-coating contains soya lecithin.
Filmska obloga vsebuje sojin lecitin.
The film-coating contains: 250 mg: polyvinyl alcohol, titanium dioxide (E171), macrogol, talc
Filmska obloga vsebuje: 250 mg: polivinilalkohol, titanov dioksid (E171), makrogol, smukec
The fimbrial adhesins F4ab, F4ac, F5, and F6 are responsible for the adhesion and the virulence of E.coli strains, which cause neonatal enterotoxicosis in piglets.
Fimbrijski adhezini F4ab, F4ac, F5 in F6 povzročajo adhezijo in virulenco sevov E. coli, ki so povzročitelji neonatalne enterotoksikoze pujskov.
The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.
Ena tretjina uporabljenega odmerka se kot nespremenjena zdravilna učinkovina izloči v seču, v glavnem z aktivno ledvično sekrecijo.
The final [90Y]-radiolabelled Zevalin solution contains up to 28 mg sodium per dose, depending on the radioactivity concentration.
Končna z [90Y] označena raztopina zdravila Zevalin vsebuje do 28 mg natrija na odmerek, odvisno od koncentracije radioaktivnosti.
The final analysis confirmed that R-CHOP treatment was associated with a clinically relevant and statistically significant improvement in the duration of event-free survival (the primary efficacy parameter; where events were death, relapse or progression of lymphoma, or institution of a new anti-lymphoma treatment) (p = 0.0001).
Končna analiza je potrdila, da je bilo zdravljenje z R-CHOP povezano s klinično pomembnim in statistično značilnim podaljšanjem trajanja preživetja brez dogodkov (primarni parameter učinkovitosti; dogodki so bili smrt, ponovitev bolezni ali napredovanje limfoma, ali uvedba novega protilimfomskega zdravljenja) (p = 0,0001).
The final analysis for OS performed after a median follow-up of 8.6 years showed no significant difference in OS between the two treatment arms.
Končna analiza OS po medianem spremljanju bolnikov 8,6 leta ni pokazala pomembne razlike v OS med obema skupinama zdravljenja.
The final analysis of OS was performed when 389 patients had died (221 in the placebo-treated group and 168 in the Perjeta-treated group).
Končna analiza celokupnega preživetja je bila izvedena, ko je umrlo 389 bolnikov (221 v skupini, ki je prejemala placebo in 168 v skupini, ki je prejemala zdravilo Perjeta).
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow- up before).
Končna analiza je bila opravljena, ko so vse bolnice prišle na pregled po 10- letnem spremljanju (razen če se jim je prej pojavil dogodek DFS ali so se prej izgubile spremljanju).
The final analysis was performed when all patients had reached their 10-year follow-up visit (unless they had a DFS event or were lost to follow-up before).
Končna analiza je bila opravljena, ko so vse bolnice prišle na pregled po 10- letnem spremljanju (razen če se jim je prej pojavil dogodek DFS ali so se prej izgubile spremljanju).
The final analysis will be performed when at least 40 patients identified with RET mutation and 40 patients identified without evidence of RET mutation have been enrolled into the study and received vandetanib for 14 months.
Končna analiza bo izvedena, ko bo vsaj 40 bolnikov z istoveteno mutacijo RET in vsaj 40 bolnikov istovetenih brez dokaza za mutacijo RET, vključenih v študijo in bodo prejemali vandetanib 14 mesecev.
The final clinical study report should be submitted after the 50th patient has 15 year follow-up visit; Q4 2037.
Končno poročilo o klinični študiji mora biti predloženo potem, ko 50. bolnik opravi obisk po 15 letih spremljanja; 4. četrtletje 2037.
The final clinical study report should be submitted by 31st March 2017
Končno poročilo o klinični študiji je treba predložiti do
The final clinical study report should be submitted by:
Končno poročilo o klinični študiji bo predloženo do:
The final concentration of 2 mg/ml is obtained by transfer of both solutions into one sterile, single-use perfusor syringe (50 ml capacity) and further dilution to a total volume of 20 ml using sodium chloride 9 mg/ml (0.9 %) or glucose 5 % solution.
Končno koncentracijo 2 mg/mL dobimo s prenosom obeh raztopin v eno sterilno perfuzijsko brizgo za enkratno uporabo (s prostornino 50 ml) in nadaljnjim redčenjem z raztopino natrijevega klorida 9 mg/mL (0,9 %) ali z raztopino 5 % glukoze do skupnega volumna 20 ml.
The final concentration of 2 mg/ml is obtained by transfer of both solutions into one sterile, single-use perfusor syringe (50 ml capacity) and further dilution to a total volume of 20 ml using sodium chloride 9 mg/ml (0.9 %) or glucose 5 % solution.
Končno koncentracijo 2 mg/mL dobimo s prenosom obeh raztopin v eno sterilno perfuzorsko brizgo za enkratno uporabo (s prostornino 50 ml) in nadaljnjim redčenjem z raztopino natrijevega klorida 9 mg/mL (0,9 %) ali z raztopino 5 % glukoze do skupnega volumna 20 ml.
The final concentration of 2 mg/ml is obtained by transfer of both solutions into one sterile, single-use perfusor syringe (50 ml capacity) and further dilution to a total volume of 50 ml using sodium chloride 9 mg/ml (0.9 %) or glucose 5 % solution.
Končno koncentracijo 2 mg/mL dobimo s prenosom obeh raztopin v eno sterilno perfuzijsko brizgo za enkratno uporabo (s prostornino 50 mL) in nadaljnjim redčenjem z raztopino natrijevega klorida 9 mg/mL (0,9 %) ali z raztopino 5 % glukoze do skupnega volumna 50 mL.
The final concentration of 2 mg/ml is obtained by transfer of both solutions into one sterile, single-use perfusor syringe (50 ml capacity) and further dilution to a total volume of 50 ml using sodium chloride 9 mg/ml (0.9 %) or glucose 5 % solution.
Končno koncentracijo 2 mg/mL dobimo s prenosom obeh raztopin v eno sterilno perfuzorsko brizgo za enkratno uporabo (s prostornino 50 ml) in nadaljnjim redčenjem z raztopino natrijevega klorida 9 mg/mL (0,9 %) ali z raztopino 5 % glukoze do skupnega volumna 50 ml.
The final concentration of 5 mg/ml is obtained by transfer into a sterile, single-use syringe (of at least 10 ml capacity) and further dilution to a total volume of 10 ml using sodium chloride 9 mg/ml (0.9 %) or glucose 5 % solution.
Končno koncentracijo 5 mg/mL dobimo s prenosom v sterilno brizgo za enkratno uporabo (s prostornino najmanj 10 ml) in nadaljnjim redčenjem z raztopino natrijevega klorida 9 mg/mL (0,9 %) ali z raztopino 5 % glukoze do skupnega volumna 10 ml.
The final concentration of 5 mg/ml is obtained by transfer into a sterile, single-use syringe (of at least 5 ml capacity) and further dilution to a total volume of 4 ml using sodium chloride 9 mg/ml (0.9 %) or glucose 5 % solution.
Končno koncentracijo 5 mg/mL dobimo s prenosom v sterilno brizgo za enkratno uporabo (s prostornino najmanj 5 ml) in nadaljnjim redčenjem z raztopino natrijevega klorida 9 mg/mL (0,9 %) ali z raztopino 5 % glukoze do skupnega volumna 4 ml.
The final concentration of Defitelio should be in the concentration range of 4 mg/mL – 20 mg/mL (see section 6.3).
Končna koncentracija zdravila Defitelio mora biti v razponu od 4 mg/ml do 20 mg/ml (glejte poglavje 6.3).
The final diluted solution in the bag or bottle should be inspected visually for particulate matter and discolouration prior to administration.
Končno razredčeno raztopino v vrečki ali steklenici pred dajanjem preglejte glede prisotnosti delcev ali obarvanja.
The final efficacy analysis included all patients randomized to both parts of the trial.
Končna analiza učinkovitosti je vključevala vse bolnike, ki so bili randomizirani v oba dela študije.
The final formulation after radiolabelling contains 2.08 mg [90Y] ibritumomab tiuxetan in a total volume of 10 ml.
Končna formulacija po označitvi z radioizotopom vsebuje 2,08 mg [90Y] ibritumomab tiuksetana v skupnem volumnu 10 ml.
The final formulation after radiolabelling contains 2.08 mg ibritumomab tiuxetan [90Y] in a total volume of 10 ml.
Končna formulacija po označevanju z radiofarmakom vsebuje 2,08 mg ibritumomab tiuksetana [90Y] v skupnem volumnu 10 ml.
The final OS analysis (12 January 2015) demonstrated a statistically significant improvement in OS for the combination compared with dabrafenib monotherapy (Figure 1).
Končna analiza celokupnega preživetja (12. januarja 2015) je pokazala statistično značilno izboljšanje celokupnega preživetja pri uporabi kombinacije v primerjavi z uporabo dabrafeniba v monoterapiji (slika 1).
The final protocol for the PASS should be
Končni protokol za študijo PASS mora biti predložen
The final radiolabelled injection solution must be protected from oxygen.
Končno radioaktivno označeno raztopino za injiciranje morate varovati pred kisikom.
The final report is expected in Q1 2018.
Končno poročilo se pričakuje v 1. četrtini leta 2018.
The final solution is to be administered in a body weight-dependent fashion (see section 4.2).
Končno raztopino moramo aplicirati v skladu s telesno maso bolnika (glejte poglavje 4.2).
The final solution is to be administered in a body weight-dependent fashion.
Končno raztopino moramo aplicirati v skladu s telesno maso bolnika.
The final solution must be inspected visually for particulate matter before administration.
Pred uporabo morate pregledati, da pripravljena raztopina ne vsebuje vidnih delcev.
The final solution should be infused over 30 minutes.
Infuzija končne raztopine mora trajati 30 minut.
The final study
študije je
The final study compared Reyataz plus either ritonavir or saquinavir with ritonavir-boosted lopinavir in 358 patients.
358 bolnikih zdravilo Reyataz v kombinaciji z ritonavirjem ali sakvinavirjem primerjali z lopinavirjem, okrepljenim z ritonavirjem.
The final study report shall be submitted by
Končno poročilo o študiji bo predloženo do
The final total volume in the container should be 250 ml.
Skupna končna prostornina v vsebniku mora znašati 250 ml.
The final volume is approximately 11.4 mL.
Končna količina je približno 11,4 ml.
The findings present following 1 month of dosing were largely reversible within 1 month of cessation of dosing with the exception of partial recovery for some of the corneal changes.
Izsledki, ugotovljeni po 1 mesecu uporabe, so bili v veliki meri reverzibilni v 1 mesecu po prenehanju uporabe z izjemo le delnega okrevanja nekaterih sprememb roženice.
The findings were observed at approximately the recommended dose in rats and 6 times the recommended dose in dogs (AUC basis).
Te izsledke so opazili pri približno priporočenem odmerku pri podganah in pri 6-kratniku priporočenega odmerka pri psih (na osnovi AUC).
The finished product is composed of one or more ethylene vinyl acetate (EVA) bags which contain an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence.
Končna oprema zdravila je ena ali več vrečk iz etilenvinilacetatata (EVA), ki vsebujejo avtologno, s CD34+ obogateno celično frakcijo s celicami CD34+, transduciranimi z retrovirusnim vektorjem, ki kodira zaporedje človeške ADA cDNA.
The first 2 numbers indicate the month; the next 4 numbers indicate the year.
Prvi 2 številki pomenita mesec, naslednje 4 številke pa leto izteka roka uporabnosti.
the first 24 hours
v prvih 24 urah
The first 330 patients were centrally assessed (response rate 6.2%); 401 patients were investigator- assessed (response rate 11.2%).
Prvih 330 bolnikov so ocenili centralno (odziv na zdravljenje 6,2 %); 401 bolnika pa so ocenili raziskovalci (odziv na zdravljenje 11,2 %).
The first administration of Cetrotide should be performed under the supervision of a physician and under conditions where treatment of possible allergic/pseudo-allergic reactions (including life- threatening anaphylaxis) is immediately available.
Prvo dajanje zdravila Cetrotide se mora izvesti pod nadzorom zdravnika in v pogojih, kjer je zdravljenje možnih alergijskih/psevdoalergijskih reakcij (vključno z življenjsko nevarno anafilaktično reakcijo) takoj na voljo.
The first CABG surgery study evaluated patients treated with IV parecoxib 40 mg bid for a minimum of 3 days, followed by treatment with valdecoxib 40 mg bid (parecoxib/valdecoxib group) (n=311) or placebo/placebo (n=151) in a 14-day, double-blind placebo-controlled study.
V prvi študiji CABG so ocenjevali bolnike, ki so jih zdravili z i.v. parekoksibom 40 mg najmanj 3 dni, čemur je sledilo zdravljenje z valdekoksibom 40 mg dvakrat na dan (skupina parekoksib/valdekoksib) (n = 311) ali prejemanje placeba/placeba (n = 151) v 14-dnevni dvojno slepi študiji, nadzirani s placebom.
The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events, or revascularisation procedure (coronary, carotid, or peripheral), or hospitalisation for heart failure.
Prvi primarni izid učinkovitosti je bil čas do prvega pojava srčno-žilne smrti, neusodnega miokardnega infarkta (MI), neusodne možganske kapi, drugi primarni izid učinkovitosti pa je bil čas do prvega pojava katerega koli od prvih primarnih dogodkov, do revaskularizacijskega posega (koronarni, karotidni ali periferni) ali do hospitalizacija zaradi popuščanja srca.
The first co=primary endpoint was the proportion of patients having a rescue free bowel movements (RFBMs) within 4 hours of the first dose administration and the second the percentage of active injections resulting in any RFBM within 4 hours during the double-blind phase.
Prvi sočasni primarni cilj študije je bil delež bolnikov z iztrebljanjem brez rešilnega odvajala v 4 urah po prvem odmerku in drugi odstotek aktivnih injiciranj, ki so povzročili iztrebljanje brez rešilnega odvajala v 4 urah med dvojno slepo fazo.
The first compared Mirapexin with placebo over 12 weeks in 344 patients and measured the improvement in symptoms.
V prvi so več kot 12 tednov primerjali zdravilo Mirapexin s placebom pri 344 bolnikih in merili izboljšanje simptomov.
The first compared ritonavir-boosted Telzir with nelfinavir (another protease inhibitor) in treatment-naïve adults (who had previously taken treatment for HIV infection for no longer than four weeks).
V prvi študiji so pri odraslih (ki se pred tem zaradi okužbe z virusom HIV niso zdravili dlje kot štiri tedne) z ritonavirjem ojačano zdravilo Telzir primerjali z nelfinavirjem (drugim zaviralcem proteaze).